Biopharmaceutical start-up TwoXar has raised $200 million to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. SoftBank has a number of funds under its wing, and the Japanese technology giant made some massive investments in 2017 through its Vision Fund. The California -based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first -stage testing in years rather than weeks . The series A funding was led by SoftBank Ventures . Andrew Radin and OS Fund also took part. TwoXar CEO Andreessen Horowitz said the use of AI in pharmaceuticals had moved from speculation to practical application and would be a “major driver” of drug development.
Biopharmaceutical start-up TwoXar has raised $200 million to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. The California -based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first -stage testing in years rather than weeks . The series A funding was led by SoftBank Ventures . Andrew Radin and OS Fund also took part. TwoXar CEO Andreessen Horowitz said the use of AI in pharmaceuticals had moved from speculation to practical application and would be a “major driver” of drug development.